Europe Anxiety Disorders And Depression Treatment Market Size & Outlook
- Pharmaceuticals
- Neurology Drugs
- Anxiety Disorders And Depression Treatment Market Outlook
- Neurology Drugs
Europe Anxiety Disorders And Depression Treatment Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask a question about the anxiety disorders and depression treatment market
Europe anxiety disorders and depression treatment market highlights
- The Europe anxiety disorders and depression treatment market generated a revenue of USD 4,516.8 million in 2024.
- The market is expected to grow at a CAGR of 3.6% from 2025 to 2030.
- In terms of segment, antidepressants was the largest revenue generating drug in 2024.
- Atypical Antipsychotics is the most lucrative drug segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 4,516.8 million |
| Market revenue in 2030 | USD 5,592.3 million |
| Growth rate | 3.6% (CAGR from 2025 to 2030) |
| Largest segment | Antidepressants |
| Fastest growing segment | Atypical Antipsychotics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents, Atypical Antipsychotics |
| Key market players worldwide | Pfizer Inc, H. Lundbeck AS Class A, GlaxoSmithKline Consumer Healthcare (GSK CH India), Merck KGaA, Eli Lilly and Co, AstraZeneca PLC, Bristol-Myers Squibb Co, Johnson & Johnson, AbbVie Inc, Sanofi SA |
Other key industry trends
- In terms of revenue, Europe region accounted for 29.3% of the global anxiety disorders and depression treatment market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 4,846.0 million by 2030.
Europe anxiety disorders and depression treatment market held substantial market share in 2024 due to significant investments in research and development for the creation of antidepressant medications. Increased sales of products for anxiety and depression disorders due to increasing in mental health awareness have furthermore assisted in the market growth for this region.
No credit card required*
Publish Date: Feb 27, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anxiety Disorders And Depression Treatment Market Scope
Anxiety Disorders And Depression Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| GlaxoSmithKline Consumer Healthcare (GSK CH India) | View profile | 1001-5000 | Gurgaon, Haryana, India, Asia | india-consumer.gsk.com/ |
| H. Lundbeck AS Class A | View profile | 5,700 | Ottiliavej 9, Valby, Denmark, 2500 | www.lundbeck.com |
Europe Anxiety Disorders And Depression Treatment Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Anxiety Disorders And Depression Treatment Market Outlook will help companies and investors design strategic landscapes.
Antidepressants was the largest segment with a revenue share of 33.38% in 2024.
Horizon Databook has segmented the Europe anxiety disorders and depression treatment market based on antidepressants, anxiolytics, anticonvulsants, noradrenergic agents, atypical antipsychotics covering the revenue growth of each sub-segment from 2018 to 2030.
Europe anxiety disorders and depression treatment market held substantial market share in 2024 due to significant investments in research and development for the creation of antidepressant medications. Increased sales of products for anxiety and depression disorders due to increasing in mental health awareness have furthermore assisted in the market growth for this region.
- Europe Anxiety Disorders And Depression Treatment Market Drug Outlook (Revenue, USD Million , 2018-2030)
- Antidepressants
- Anxiolytics
- Anticonvulsants
- Noradrenergic Agents
- Atypical Antipsychotics
- Europe Anxiety Disorders And Depression Treatment Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Depression
- Anxiety
- Europe Anxiety Disorders And Depression Treatment Market Distribution Channel Outlook (Revenue, USD Million , 2018-2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to Anxiety Disorders And Depression Treatment Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Anxiety Disorders And Depression Treatment Market Outlook databook
- Our clientele includes a mix of Anxiety Disorders And Depression Treatment Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Anxiety Disorders And Depression Treatment Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Anxiety Disorders And Depression Treatment Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Europe Anxiety Disorders And Depression Treatment Market, 2018-2030 (US$M)
Europe anxiety disorders and depression treatment market statistics, by drug, 2018-2030 (US$M)
